Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hummel

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
Circulation|November 17, 2017
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled TrialTed Feldman, Laura Mauri, Rami Kahwash, et al.
Circulation|March 24, 2020
Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group SummarySanjiv J Shah, Barry A Borlaug, Dalane W Kitzman, et al.
JAMA Cardiology|April 17, 2024
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical TrialRavi B Patel, Frank E Silvestry, Jan Komtebedde, et al.
European Heart Journal|August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypesMichele Senni, Walter J Paulus, Antonello Gavazzi, et al.
Journal of the American College of Cardiology|July 9, 2016
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)Mathew S Maurer, Mazen Hanna, Martha Grogan, et al.
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
European Journal of Heart Failure|November 21, 2023
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trialSheldon E Litwin, Jan Komtebedde, Tim Seidler, et al.
Journal of the American College of Cardiology|September 10, 2021
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art ReviewAmbarish Pandey, Sanjiv J Shah, Javed Butler, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Circulation|November 17, 2017
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled TrialTed Feldman, Laura Mauri, Rami Kahwash, et al.
Circulation|March 24, 2020
Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group SummarySanjiv J Shah, Barry A Borlaug, Dalane W Kitzman, et al.
JAMA Cardiology|April 17, 2024
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical TrialRavi B Patel, Frank E Silvestry, Jan Komtebedde, et al.
European Heart Journal|August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypesMichele Senni, Walter J Paulus, Antonello Gavazzi, et al.
Journal of the American College of Cardiology|July 9, 2016
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)Mathew S Maurer, Mazen Hanna, Martha Grogan, et al.
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
European Journal of Heart Failure|November 21, 2023
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trialSheldon E Litwin, Jan Komtebedde, Tim Seidler, et al.
Journal of the American College of Cardiology|September 10, 2021
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art ReviewAmbarish Pandey, Sanjiv J Shah, Javed Butler, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Pageof 23